
BCTX Stock Forecast & Price Target
BCTX Analyst Ratings
Bulls say
BriaCell Therapeutics has recently received a non-dilutive $2 million grant from the US National Cancer Institute to advance its Bria-PROS+ program, which is crucial for its clinical development in metastatic prostate cancer. This funding will facilitate the completion of clinical supply manufacturing and support the ongoing Phase 1/2a trials for Bria-OTS, enhancing the company's portfolio of immunotherapy solutions. The successful advancement of these programs indicates BriaCell's strong position and potential for growth in the biotechnology sector focused on innovative cancer treatments.
Bears say
BriaCell Therapeutics faces several significant risks that contribute to a negative outlook for the company's stock, including potential safety signals emerging from clinical programs and lower-than-expected efficacy in ongoing studies. The company anticipates needing approximately $120 million in additional financing through 2037, raising concerns about its financial stability and ability to fund operations. Furthermore, the competitive landscape for cancer treatments poses additional pressure, with existing and developing alternatives, along with possible regulatory challenges impacting the commercialization of BriaCell's immunotherapies.
This aggregate rating is based on analysts' research of BriaCell Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BCTX Analyst Forecast & Price Prediction
Start investing in BCTX
Order type
Buy in
Order amount
Est. shares
0 shares